Monograph Details
|
|
Urogenital System
> Miscellaneous urogenital disorders
|
|
RENAGEL TABLETS |
| Manufacturer |
|
Genzyme Corporation |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Phosphate binder. |
| Generic Name |
|
Sevelamer HCl 400mg, 800mg. |
| Indications |
|
Reduction of serum phosphorus in end stage renal disease in patients on hemodialysis. |
| Children |
|
Not recommended. |
| Adults |
|
Swallow whole with meals. Patients not taking a phosphate binder: serum phosphorus >5.5 to <7.5mg/dL: 800mg 3 times daily; 7.5–9mg/dL: 1.2–1.6g 3 times daily; ≥9mg/dL: 1.6g 3 times daily. Titrate by 1 tab per meal at 2-week intervals to keep serum phosphorus ≤5.5mg/dL. Switching from calcium acetate to sevelamer: see literature. |
| Contraindications |
|
Hypophosphatemia. Bowel obstruction. |
| Precautions |
|
Dysphagia. Swallowing disorders. Severe GI motility disorders. Major GI tract surgery. Monitor serum calcium, bicarbonate, chloride. Pregnancy (Cat.C). |
| Interactions |
|
Separate narrow therapeutic index drugs by 1 hr before or 3 hrs after sevelamer, or monitor. |
| Adverse Reactions |
|
GI upset, headache, constipation. |
| How Supplied |
Tabs 400mg—360
Tabs 800mg—180 |
|
|
|
|
